Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Myosin Inhibition in Non-obstructive Hypertrophic Cardiomyopathy: Lessons from ODYSSEY-HCM.

European cardiology·2026
Same author

Cardio-oncology, from Guidelines to Practice: Filling the Gap - an Eastern European Viewpoint.

European cardiology·2026
Same author

Kidney disease increases the risk of cardiovascular events in patients with device-detected atrial fibrillation: NOAH-AFNET 6.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Quality of life, care needs and priorities in atrial fibrillation: the impact of number and patterns of comorbidities.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2026
Same author

The role of comorbidity and frailty in shaping the burden of atrial fibrillation: a multinational cross-sectional survey.

Scientific reports·2026
Same author

No DECAF Coffee for Me, Please!

European cardiology·2026
Same journal

Associations between anthropometric measures and cardiovascular risk biomarkers in women with short stature.

JRSM cardiovascular disease·2026
Same journal

Virtual population-based analysis of anatomical and electrophysiological risk markers for atrial fibrillation.

JRSM cardiovascular disease·2026
Same journal

Isolated and combined effects of papillary muscle approximation and mitral annuloplasty in dilated left ventricles.

JRSM cardiovascular disease·2026
Same journal

Shape and flow characterization of the pulmonary arteries after the LeCompte maneuver.

JRSM cardiovascular disease·2026
Same journal

Analysis of cardiac dynamic global function.

JRSM cardiovascular disease·2026
Same journal

The inverse problem of electrocardiography: From a clinical point of view.

JRSM cardiovascular disease·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Lipid-lowering therapy: Evidence and future perspective.

Maki Komiyama1, Hiromichi Wada1, Gheorghe-Andrei Dan2

  • 1Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

JRSM Cardiovascular Disease
|May 29, 2026
PubMed
Summary
This summary is machine-generated.

Lowering LDL-C is crucial for preventing atherosclerotic cardiovascular disease (ASCVD). New therapies targeting triglycerides and Lipoprotein(a) [Lp(a)] offer hope for reducing residual cardiovascular risk.

Keywords:
LDL cholesterolLipid-lowering therapyPCSK9 inhibitorslipoprotein(a)residual cardiovascular risktriglycerides

Related Experiment Videos

Last Updated: May 31, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiovascular Medicine
  • Lipidology
  • Pharmacology

Background:

  • Lowering low-density lipoprotein cholesterol (LDL-C) is a primary strategy for atherosclerotic cardiovascular disease (ASCVD) prevention.
  • Guidelines recommend intensive LDL-C reduction (<70 mg/dL or <55 mg/dL) for high-risk patients.
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors significantly reduce LDL-C and cardiovascular events.

Purpose of the Study:

  • To review current strategies for LDL-C lowering in ASCVD prevention.
  • To discuss the role of emerging therapies targeting triglycerides and Lipoprotein(a) [Lp(a)].
  • To explore future directions in comprehensive lipid management for residual risk reduction.

Main Methods:

  • Review of current guidelines and clinical trial data on lipid-lowering therapies.
  • Analysis of evidence for PCSK9 inhibitors, triglyceride-lowering agents, and Lp(a)-targeted therapies.
  • Discussion of residual cardiovascular risk and personalized risk stratification.

Main Results:

  • Intensive LDL-C lowering with statins and PCSK9 inhibitors is effective, especially in high-risk populations.
  • Triglyceride-lowering therapies have shown inconsistent cardiovascular benefits.
  • Elevated Lipoprotein(a) [Lp(a)] is an independent ASCVD risk factor, with novel therapies demonstrating significant reduction.

Conclusions:

  • Future ASCVD prevention requires integrated strategies beyond LDL-C reduction.
  • Addressing residual risk through novel targets like Lp(a) is essential.
  • Personalized risk stratification will optimize treatment efficacy and cost-effectiveness.